

Review of *M. ovi* management strategies

Kezia Manlove

Contracted to
BC Ministry of Agriculture and FLNRO

Thanks to:

BC Ministry of Agriculture, FLNRO, and BC Sheep Working Group

- Tom Besser (retired!)
- Becky Schwanke (AK WSF)
- Maggie Highland (Kansas State)
- Chad Lehman and others at SDGFP
- Austin Weiseler (SDSU)
- Blake Lowrey (MTFWP/MSU)
- Kevin White (Alaska Game and Fish)
- Frances Cassirer (IDFG)
- Mandy Kauffman (Western Ecosystems Technology)
- Helen Schwantje (BC FLNRO)
- Jace Taylor (UDWR)
- Mike Cox (NDOW)
- Peri Wolff (NDOW/WDA)
- Kelly McAllister (Washington Dept of Transport.)
- Marcel Huijser (Western Transportation Institute)
- Brandi Felts (IDFG)

Review/Sythesize current knowledge on the following:

- Approaches and best-practices for eradicating *M. ovi* from domestic sheep and goat operations
- History and performance of diagnostic testing for *M. ovi*
- Host range and potential role of non-non-caprine species in epidemiology of *M. Ovi*
- Relative risk of *M. Ovi* transmission for domestic goats as compared to domestic sheep
- Costs and benefits of various fencing strategies to limit risk of M. Ovi transmission
- Likely risk and consequences of M. Ovi transmission into mountain goats and thinhorns
- Utility of M. ovi strain typing and variation in virulence of particular strains

Table of all documented *M. ovi* events / detections in mountain goats

PRELIMINARY – PLEASE CONTACT K. MANLOVE PRIOR TO CIRCULATION/REPLICATION.

Location (state)	Year	Lab	PCR (N/ +/-)	Serology (N/ +/-)	Sympatric with Bighorn / shared strain	Demographic consequences	Source
Northeast GYA (WY)	2013	WADDL/ WGF	14/3/10		Yes/		Lowrey et al. 2018a; demography from Smith and DeCesare
Northeast GYA	2014	WADDL	7/1/5	7/2/4	Yes/		Lowrey et al. 2018a
Southwest GYA	2013	WADDL	13/0/13	7/6/1	No/		Lowrey et al. 2018a
Southwest GYA (ID)	2014	WGF	9/9/0		No/		Lowrey et al. 2018a
Southwest GYA	2015	WGF	4/2/2		No/		Lowrey et al. 2018a
Southwest GYA	2017	WGF	4/2/1		No/		Lowrey et al. 2018a
Grand Teton NP (WY)	2014	WGF	5/0/5	5/0/5	Yes/		Lowrey et al. 2018a
Grand Teton NP (WY)	2015	WGF	4/0/4	4/0/4	Yes/		Lowrey et al. 2018a
Grand Teton NP (WY)	2017	WGF	5/0/5	4/0/4	Yes/		Lowrey et al. 2018a
Southeast Alaska	2010	WADDL	19/0/19		No/		Lowrey et al. 2018a
Southeast Alaska	2014	WADDL	14/0/14	16/0/16	No/		Lowrey et al. 2018a
East Humboldts (NV)	2010	WADDL	3/1/-	3/3/-	Yes/Yes	Estimated 13% decline in mtn goat pop size (Cox et al. 2017)	Wolff et al. 2019
East Humboldts (NV)	2012	WADDL	2/0/-	2/2/-	Yes/Yes		Wolff et al. 2019
East Humboldts (NV)	2013	WADDL	15/1/-	15/14/-	Yes/Yes	Summer kid survival estimated at 0.19 (Blanchong et al. 2018)	Wolff et al. 2019
East Humboldts (NV)	2014	WADDL	16/2/-	16/14/-	Yes/Yes	Summer kid survival estimated at 0.19 (Blanchong et al. 2018)	Wolff et al. 2019

Mountain Goat / *M. ovi* data

- Lowrey et al. 2018 data
 - NE GYA
 - SW GYA
 - Grand Teton NP
 - SE Alaska
- Cox/Wolff/Blanchong with demography
 - NV — East Humboldts
 - NV — Rubys
- Strains in Kamath et al. *M. ovi* phylogeny paper
 - UT — Timpanagos
 - UT — Willard Peak
 - MT — Castle Creek/Tom Miner
 - SD — Battle Creek

Table of drugs tested against *M. ovi*

PRELIMINARY — PLEASE CONTACT K. MANLOVE PRIOR TO CIRCULATION/REPLICATION.

Drug group	Active ingredient (drug)	Delivery/ schedule	Efficacy in domestic sheep	Licensed for administration in lambs?	Other considerations
fluoroquinolone	Enrofloxacin (Baytril)	Politis notes 3-5 administrations of 5-10 mg/kg body weight (consecutive days)	Note: Goncalves et al. 2010 also suggests enrofloxacin should be effective in goats. Besser (2018) trial showed little effect of injectable Baytril alone.	Yes.	Disallowed in US meat chain. "Adverse effects of fluoroquinolone administration include excretion of yellow faeces and possible damage to connective tissue (e.g., tendinopathies, arthritis lesions), which preclude their use in lambs to be maintained as replacement animals." (Politis et al., 2019).
fluoroquinolone	Difloxacin (Dicural)	Subcutaneous injection 4.0 mg/kg body weight one daily for 3 consecutive days (in lambs in Mavrogianni)	Good -- Mavrogianni. No <i>Movi</i> detected after treatment (at this dosage)		
fluoroquinolone	Marbofloxacin	Subcutaneous injection of 2-3 mg/kg bw (depending on treatment schedule) (Skoufos et al. 2007 Small Rum Res).	"Two high or three low doses of marbofloxacin, i.e. a total of ≥ 6.0 mg/kg bodyweight, were needed for effective treatment. Two low doses, i.e. a total of 4.0 mg/kg bodyweight, were not found effective."(Skoufos 2007 discussion)		"no local reactions were recorded in any lamb injected with marbofloxacin." (Skoufos et al. 2007)
macrolide	Tilmicosin (Micotil)	Subcutaneous infection with 15 mg/kg bw twice, four days apart (Mavrogianni). Also used in Skoufos et al. 2007, also effective there, also noted emergence of resistance. Politis notes standard dosing	Looked pretty good to me in terms of weight gain, but Mavrogianni prefers difloxacin. No <i>Movi</i> detected after treatment.	Yes.	"It is noteworthy however, that recent papers (Ayling et al., 2000a,b) have reported the finding of tilmicosin-resistant strains of <i>Mycoplasma</i> spp." (from Mavrogianni pg. 327)

Table of test-remove or test-treat efforts in domestics

PRELIMINARY – PLEASE CONTACT K. MANLOVE PRIOR TO CIRCULATION/REPLICATION.

Species (date)	Operation size	Rounds of testing	# Tested/ Positive/ Negative	Age/sex classes included	Who paid	Method for removal	Follow-up testing/ Status
Goats (Jan 2018)	17 (+ 3 kids = 20)	3 (2 for 3 new kids) @ months 1, 2, 3; all qPCR	20/3(+31)/14 on round 1; on re-test, 20/8/12. All in all, 10 tested positive and were removed; 5 others died	Adults & kids	Alaska Wild Sheep Foundation	Quarantined and eventually culled	5 remaining goats tested July and were PCR-negative. 6 replacement animals were also tested, and were all negative
Goats (Jan 2019)	14	3 @ months, 1, 3, 4 (qPCR & cELISA)	14/2/12	Bucks, does, kids	Alaska Wild Sheep Foundation	Both bucks positive and were culled; 3 others died from other causes	9 remaining + 11 kids tested 6 months later (October); all qPCR negative
Sheep (June 2020)				Ewes, lambs	USFWS/ WSU/ USU	Culled five chronically infected ewes	
Sheep (~2017?)	~50	3 initially,		all	IDFG, Rocky Crate	Culled 1 lamb initially, more culls required by subsequent reintroduction	3 negative whole herd, then owner purchased infected rams to reintroduce

Data from

- Becky Schwanke
- Helen Schwantje
- Tom Besser (with IDFG)
- USWFS (with Tom Besser)

Table of fencing cost-benefits

PRELIMINARY – PLEASE CONTACT K. MANLOVE PRIOR TO CIRCULATION/REPLICATION.

Distance from core herd home range	Probability a foraging animal goes this far	Ratio adjustment (assume 1km of operation boundary, and 100 km circumference of round bighorn core area)	Annual proportion of herd expected to foray this far	# animals expected to become infected (assuming bighorn herd has 25 males, with infection probabilities described below)	Waiting time to infection from this operation (years)	Expected proportion of years with disease (= persistence time/ waiting time)	Expected cost (= pers to waiting * annual disease cost)	Annual benefit from fencing (assuming fencing reduces risk by 90%)
1 km	1	0.0048	$0.0048 \times 0.179 = 0.00087$	$0.00087 \times 25 \times 0.876 = 0.0190$	52.62	0.21	\$40,510.38	\$36,459.34
5 km	0.80	0.0043	$0.0043 \times 0.179 = 0.00077$	$0.00077 \times 25 \times 0.876 = 0.0169$	59.03	0.19	\$36,110.78	\$32,499.71
10 km	0.55	0.0038	$0.0038 \times 0.179 = 0.00068$	$0.00068 \times 25 \times 0.876 = 0.0149$	67.05	0.16	\$31,794.51	\$28,615.06
20 km	0.23	0.0030	$0.0030 \times 0.179 = 0.00055$	$0.00055 \times 25 \times 0.876 = 0.0120$	83.08	0.13	\$25,660.24	\$23,094.22
30 km	0.04	0.0026	$0.0026 \times 0.179 = 0.00046$	$0.00007 \times 25 \times 0.876 = 0.0101$	99.10	0.11	\$21,510.18	\$19,359.16



How do you test for *M. ovi* in bighorn and domestic sheep and goats?

- First, you need to know some basic facts about this bacteria, *Mycoplasma ovipneumoniae*.
- Second, you need to know how to handle blood samples from sheep and goats.
- Third, you need to know how to handle bighorn sheep.
- Antibiotics can be used to clear *M. ovi* from domestic sheep and goat operations.



Clearing *M. ovipneumoniae* from domestic sheep and goat operations

Removing the bacteria *Mycoplasma ovipneumoniae* (*M. ovi*) from a group of domestic sheep or goats will benefit producers by improving lamb or kid weight gain, as well as overall herd health.



Fencing strategies to separate bighorn and domestic sheep



Sheep, wild sheep, and risk of pneumonia


Mycoplasma ovipneumoniae (*M.OV*) POSES A MAJOR THREAT TO WILD SHEEP IN NORTH AMERICA.

...in height. However, most...
...and this seems to al...
...ns merit consideration.
...tain animal movements

48% median decline in bighorn pneumonia events

~88% of US domestic sheep and goats carry *M. ovi*. Wildlife agencies need your help.

How an *M. ovi*-associated die-off works?



Mycoplasma ovipneumoniae and Mountain Goats

Mycoplasma ovipneumoniae ("*M. ovi*") can infect and cause disease in mountain goats.



Mycoplasma ovipneumoniae and domestic goats

Domestic goats can carry *Mycoplasma ovipneumoniae* (*M. ovi*) strains that can cause disease in wild sheep and goats.

However, goats likely pose a lower risk to wild sheep and goats.

Little is known about *M. ovi* in meat, dairy, and wool.

- M. ovi* prevalence in pack goats is likely much lower than in domestic goats.
- One study of over 500 pack goats from over 80 farms found that less than 10% of these goats were older than 10 years, and of those, less than 5% were older than 20 years.
- For domestic sheep, one study found an average prevalence near 50%.
- We do not know why this difference exists.

M. ovi strains in domestic goats may be different from strains in domestic sheep

- M. ovi* bacteria can be classified into different strains, and different animals can be infected with different strains.
- Some strains in domestic goats appear to be unique and different from those in domestic sheep.
- These "goat clade" strains, if transmitted to bighorns, may have different effects than strains arising from domestic sheep.
- However, "sheep clade" strains can still produce disease in bighorns.



M. ovipneumoniae infections in animals other than sheep and goats

M. ovi was detected in at least eight different free-ranging mountain goat populations. Mountain goats linked with pneumonia events in mountain goats similar to those observed in domestic goats.

When mountain goats are sympatric with bighorn sheep populations, they sometimes share the same *M. ovi* strain. However, some sympatric herds do not share strains, and wild goats can be infected even when they do not overlap with bighorn herds. Limited information about effects of *M. ovi* on mountain goat population health.

In all-studied cases, the effect of *M. ovi* on mountain goats was similar to its effect on bighorn sheep: all-age die-off events followed by reduced kid recruitment.

Local factors that may make mountain goats less susceptible to *M. ovi*.

Next steps

- Solicit any additional information for WSWG (right this minute!)
- Products will go through BC approval process
 - Distribution & sharing decisions will be made by BC
- Follow-ons
 - Peer review? (maybe as a whole; maybe as smaller chunks)
 - Collaborative manuscript on eradication efforts in domestics
 - Longer-term effort toward manuscript on costs/benefits of various management options

[https://forms.gle/
KHMgcu2kjycfWqbz8](https://forms.gle/KHMgcu2kjycfWqbz8)

Name

Short-answer text

Email address & phone number (& which method you'd prefer for contact)

Short-answer text

I have information I could contribute about the following

- An Movi eradication effort in domestic sheep or goats
- Movi testing information or disease information for MOUNTAIN GOATS
- Movi testing information for LLAMAS OR ALPACAS
- Movi testing information for OTHER SPECIES
- Drug treatment efforts for Movi
- Cost information for FENCING, TREATMENT, ERADICATION, or DEPOPULATION management of Movi in an...
- Other...

Description/anecdote/whatever else you want to tell me.